Radiotherapy and Oncology, 24 (1992) 283 © 1992 Elsevier Science Publishers B.V. 0167-8140/92/$05.00 283

SUBJECT INDEX

Accidental irradiations, 21 Adjuvant radiotherapy, 191 Alkylating chemotherapy, 239 Asymmetric field inversion gel electrophore-

sis, 231

Bile duct cancer, 198 Biodistribution, 169 Biological dosimetry, 21 Bioreductive drug, 201 Bladder dose, 137 Brachytherapy, 147 Brain, 186 Breast irradiation, 94, 251 Bulky cervical cancer, 32 B vitamin, 75

Carbogen, 75 Carcinoma of nasal fossa, 163 Cervical carcinoma, 137 Chemotherapy, 14, 114 Cisplatin, 60 Combination therapy, 32 Combined surgery and irradiation, 87 Complication, 163 Computed tomography, 94 Computed Tomography, 117 Computer treatment planning, 147 Conformal field therapy, 261 CT-assisted dosimetry, 137 Cutaneous T-cell lymphoma, 155 Cytotoxic drugs, 177

Decision rules, 261 Dipyridamole, 246 DNA rejoining, 231 Dose calculations, 55 Dose dependence, 21 Dose-response analysis, 1 Dose volume histogram, 198 Dose-volume histogram, 251 Dosimetry, 82 Dysphagia, 114

Electron therapy, 251 Endometrial carcinoma, 137 Esophageal carcinoma, 114 Extradural, 14

Film dosimetry, 137

Head and neck cancer, 27

Head scatter, 55 High dose-rate brachytherapy, 137 Hodgkin's disease, 1 Human tumor cell, 60 Human tumor cell line, 102, 201

In-field control, 1 Integral probability model, 251 Interaction, 177 Interstitial therapy, 251 Intrinsic radiosensitivity, 102, 201,231

Large fraction, 195 Local control, 163 Local recurrence, 41 Locoregional tumor control, 87 Lung, 177 Lymphoma, 169

M7 multicentric protocol, 77 Magnetic resonance imaging, 82 Malignant melanoma, 195 Mediastinum, 226 Medulloblastoma, 77 Monoclonal antibody, 169 Mouse, 177 Multi-cell spheroids, 239

Nicotinamide, 75 Nitrofurans, 239 Non-Hodgkin's lymphoma, 14 Normal tissue complication probabilities,

251 Nude mice, 186

Oesophagus, 108 On-line portal imaging, 45 Oxic conditions, 60

Pancreatic cancer, 191, 198 Patient setup verification, 261 Personal computer, 117 Phosphorus-31 magnetic resonance spec-

troscopy, 186 Plateau-phase cultures, 102 PLD repair, 246 Pneumonitis, 177 Portal imaging, 261 Positioning, 94 Postoperative irradiation, 87 Predictive assay, 231

Preoperative radiotherapy, 108 Primitive neuroectodermic tumour, 77 Prognostic factors, 32 Prostatic cancer, 261

Quality assurance, 147, 261

Radiation, 177 Radiation chemistry, 82 Radiation field alignment, 261 Radiation-induced hyperamylasemia, 21 Radiation therapy, 14, 82, 221, 246, 261 Radiation treatment planning, 117, 198 Radioimmunotherapy, 169 Radiosensitizer, 246 Radiosurgery, 82 Radiotherapy, 27, 41, 114, 155, 163, 186,

195, 226 Radiotherapy and cisplatin interaction, 60 Randomized trial, 108 Rectal dose, 137 Renal cell cancer, 41 Renal toxicity, 198 Reproducibility, 94

Salivary glands, 27 Scar recurrence, 41 Seminoma, 226 Serum amylase, 27 Shielding blocks, 55 Small cell lung cancer (SCLC), 186 Solid tumor, 239 Split-dose recovery, 102 Squamous cell carcinoma, 32 Squamous cell carcinoma of the head and

neck, 87 SR-4233, 201 Survival, 87, 163

T 2 and T3, control of laryngeal cancer, 215 Telecontrolled patient couch, 45 Three-dimensional treatment planning, 94 Thymoma, 221 TLD dosimetry, 137 Total skin electron irradiation, 155 Treatment time, 215 Tumour imaging, 117 Tumour relapse, 77

Volume effect, 251

Xenogra~s, 186